Abstract：
Non-small cell lung cancer (NSCLC) poses a global health threat, and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) such as gefitinib, afatinib, and osimertinib have achieved significant success in clinical treatment. However, the emergence of resistance limits the long-term efficacy of these treatments, necessitating urgent exploration of novel EGFR-TKIs. This review provides an in-depth summary and exploration of the resistance mechanisms associated with EGFR-TKIs, with a specific focus on representative drugs like gefitinib, afatinib, and osimertinib. Additionally, the review introduces a therapeutic strategy involving the combination of Chinese herbal medicines (CHMs) and chemotherapy drugs, highlighting the potential role of CHMs in overcoming NSCLC resistance. Through systematic analysis, we elucidate the primary resistance mechanisms of EGFR-TKIs in NSCLC treatment, emphasizing CHMs as potential treatment medicines and providing a fresh perspective for the development of next-generation EGFR-TKIs. This comprehensive review aims to guide the application of CHMs in combination therapy for NSCLC management, fostering the development of more effective and comprehensive treatment modalities to ultimately enhance patient outcomes.
摘要：
非小细胞肺癌（NSCLC）构成全球健康威胁，和表皮生长因子受体-酪氨酸激酶抑制剂（EGFR-TKIs）如吉非替尼，阿法替尼,和奥希替尼在临床治疗中取得了显著成功。然而,耐药性的出现限制了这些治疗的长期疗效，迫切需要探索新的EGFR-TKIs。本文对EGFR-TKIs的耐药机制进行了深入的总结和探索。特别关注吉非替尼等代表性药物，阿法替尼,和奥希替尼。此外,该综述介绍了一种涉及中草药（CHMs）和化疗药物组合的治疗策略，强调CHM在克服NSCLC耐药中的潜在作用。通过系统分析,我们阐明EGFR-TKIs在NSCLC治疗中的主要耐药机制，强调CHM是潜在的治疗药物，并为下一代EGFR-TKIs的开发提供了新的视角。本综述旨在指导CHMs在非小细胞肺癌综合治疗中的应用。促进开发更有效和全面的治疗方式，以最终提高患者的治疗效果。
